Is PRME or GNLX more profitable?

Genelux has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Genelux's return on equity of -174.55% beat Prime Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Prime Medicine -4,917.55% -188.82% -60.97% Genelux N/A -174.55% -123.65%

Does the media refer more to PRME or GNLX?

In the previous week, Prime Medicine and Prime Medicine both had 3 articles in the media. Genelux's average media sentiment score of 1.89 beat Prime Medicine's score of 0.63 indicating that Genelux is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genelux 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better earnings & valuation, EIKN or GNLX?

Eikon Therapeutics has higher earnings, but lower revenue than Genelux. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eikon Therapeutics N/A N/A N/A N/A N/A Genelux $8K 16,702.90 -$32.15M -$0.85 N/A

Is EIKN or GNLX more profitable?

Eikon Therapeutics' return on equity of 0.00% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Eikon Therapeutics N/A N/A N/A Genelux N/A -174.55% -123.65%

Does the media favor EIKN or GNLX?

In the previous week, Eikon Therapeutics had 3 more articles in the media than Genelux. MarketBeat recorded 6 mentions for Eikon Therapeutics and 3 mentions for Genelux. Genelux's average media sentiment score of 1.89 beat Eikon Therapeutics' score of 0.69 indicating that Genelux is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eikon Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genelux 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher valuation & earnings, PRTA or GNLX?

Genelux has lower revenue, but higher earnings than Prothena. Genelux is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prothena $57.94M 7.98 -$244.09M -$2.82 N/A Genelux $8K 16,702.90 -$32.15M -$0.85 N/A

Is PRTA or GNLX more profitable?

Genelux has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Prothena's return on equity of -43.44% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Prothena -260.92% -43.44% -36.87% Genelux N/A -174.55% -123.65%

Is KYTX or GNLX more profitable?

Kyverna Therapeutics' return on equity of -81.88% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Kyverna Therapeutics N/A -81.88% -64.87% Genelux N/A -174.55% -123.65%

Does the media prefer KYTX or GNLX?

In the previous week, Kyverna Therapeutics had 4 more articles in the media than Genelux. MarketBeat recorded 7 mentions for Kyverna Therapeutics and 3 mentions for Genelux. Genelux's average media sentiment score of 1.89 beat Kyverna Therapeutics' score of 0.63 indicating that Genelux is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genelux 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is CTNM or GNLX more profitable?

Contineum Therapeutics' return on equity of -27.09% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Contineum Therapeutics N/A -27.09% -25.64% Genelux N/A -174.55% -123.65%

Does the media refer more to CTNM or GNLX?

In the previous week, Genelux had 1 more articles in the media than Contineum Therapeutics. MarketBeat recorded 3 mentions for Genelux and 2 mentions for Contineum Therapeutics. Genelux's average media sentiment score of 1.89 beat Contineum Therapeutics' score of 0.93 indicating that Genelux is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genelux 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Genelux (GNLX) Competitors

$2.98 +0.03 (+1.02%)

As of 02:16 PM Eastern

Compare

GNLX vs. PRME, EIKN, PRTA, KYTX, and CTNM

Should you buy Genelux stock or one of its competitors? MarketBeat compares Genelux with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genelux include Prime Medicine (PRME), EIKN (EIKN), Prothena (PRTA), Kyverna Therapeutics (KYTX), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical products" industry.

How does Genelux compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and Genelux (NASDAQ:GNLX) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Genelux has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Genelux's return on equity of -174.55% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
Genelux	N/A	-174.55%	-123.65%

Prime Medicine presently has a consensus price target of $7.65, indicating a potential upside of 144.72%. Genelux has a consensus price target of $18.00, indicating a potential upside of 504.03%. Given Genelux's higher possible upside, analysts clearly believe Genelux is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Prime Medicine and Prime Medicine both had 3 articles in the media. Genelux's average media sentiment score of 1.89 beat Prime Medicine's score of 0.63 indicating that Genelux is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genelux	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Genelux has lower revenue, but higher earnings than Prime Medicine. Genelux is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.03M	139.96	-$201.14M	-$1.23	N/A
Genelux	$8K	16,702.90	-$32.15M	-$0.85	N/A

70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 37.3% of Genelux shares are held by institutional investors. 16.0% of Prime Medicine shares are held by insiders. Comparatively, 7.5% of Genelux shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Prime Medicine has a beta of 2.31, indicating that its stock price is 131% more volatile than the broader market. Comparatively, Genelux has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

Summary

Prime Medicine beats Genelux on 8 of the 15 factors compared between the two stocks.

How does Genelux compare to Eikon Therapeutics?

Eikon Therapeutics (NASDAQ:EIKN) and Genelux (NASDAQ:GNLX) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

37.3% of Genelux shares are owned by institutional investors. 7.5% of Genelux shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Eikon Therapeutics' return on equity of 0.00% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eikon Therapeutics	N/A	N/A	N/A
Genelux	N/A	-174.55%	-123.65%

Eikon Therapeutics has higher earnings, but lower revenue than Genelux.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A
Genelux	$8K	16,702.90	-$32.15M	-$0.85	N/A

Eikon Therapeutics presently has a consensus target price of $25.20, indicating a potential upside of 168.77%. Genelux has a consensus target price of $18.00, indicating a potential upside of 504.03%. Given Genelux's stronger consensus rating and higher possible upside, analysts clearly believe Genelux is more favorable than Eikon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Eikon Therapeutics had 3 more articles in the media than Genelux. MarketBeat recorded 6 mentions for Eikon Therapeutics and 3 mentions for Genelux. Genelux's average media sentiment score of 1.89 beat Eikon Therapeutics' score of 0.69 indicating that Genelux is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eikon Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genelux	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Genelux beats Eikon Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Genelux compare to Prothena?

Prothena (NASDAQ:PRTA) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, Genelux had 1 more articles in the media than Prothena. MarketBeat recorded 3 mentions for Genelux and 2 mentions for Prothena. Genelux's average media sentiment score of 1.89 beat Prothena's score of 1.62 indicating that Genelux is being referred to more favorably in the news media.

Company	Overall Sentiment
Prothena	Very Positive
Genelux	Very Positive

Prothena has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market. Comparatively, Genelux has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

97.1% of Prothena shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 10.4% of Prothena shares are owned by company insiders. Comparatively, 7.5% of Genelux shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Genelux has lower revenue, but higher earnings than Prothena. Genelux is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$57.94M	7.98	-$244.09M	-$2.82	N/A
Genelux	$8K	16,702.90	-$32.15M	-$0.85	N/A

Prothena presently has a consensus price target of $23.75, suggesting a potential upside of 168.82%. Genelux has a consensus price target of $18.00, suggesting a potential upside of 504.03%. Given Genelux's higher possible upside, analysts plainly believe Genelux is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Genelux has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Prothena's return on equity of -43.44% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-260.92%	-43.44%	-36.87%
Genelux	N/A	-174.55%	-123.65%

Summary

Prothena beats Genelux on 9 of the 17 factors compared between the two stocks.

How does Genelux compare to Kyverna Therapeutics?

Kyverna Therapeutics (NASDAQ:KYTX) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

In the previous week, Kyverna Therapeutics had 4 more articles in the media than Genelux. MarketBeat recorded 7 mentions for Kyverna Therapeutics and 3 mentions for Genelux. Genelux's average media sentiment score of 1.89 beat Kyverna Therapeutics' score of 0.63 indicating that Genelux is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genelux	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Genelux has higher revenue and earnings than Kyverna Therapeutics. Genelux is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A
Genelux	$8K	16,702.90	-$32.15M	-$0.85	N/A

Kyverna Therapeutics currently has a consensus price target of $30.00, indicating a potential upside of 287.10%. Genelux has a consensus price target of $18.00, indicating a potential upside of 504.03%. Given Genelux's higher possible upside, analysts plainly believe Genelux is more favorable than Kyverna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 37.3% of Genelux shares are held by institutional investors. 17.6% of Kyverna Therapeutics shares are held by company insiders. Comparatively, 7.5% of Genelux shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Kyverna Therapeutics' return on equity of -81.88% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.88%	-64.87%
Genelux	N/A	-174.55%	-123.65%

Kyverna Therapeutics has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market. Comparatively, Genelux has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

Summary

Kyverna Therapeutics beats Genelux on 8 of the 14 factors compared between the two stocks.

How does Genelux compare to Contineum Therapeutics?

Contineum Therapeutics (NASDAQ:CTNM) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Contineum Therapeutics' return on equity of -27.09% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-27.09%	-25.64%
Genelux	N/A	-174.55%	-123.65%

37.3% of Genelux shares are held by institutional investors. 11.3% of Contineum Therapeutics shares are held by insiders. Comparatively, 7.5% of Genelux shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Contineum Therapeutics has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market. Comparatively, Genelux has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

Contineum Therapeutics presently has a consensus target price of $20.00, suggesting a potential upside of 58.35%. Genelux has a consensus target price of $18.00, suggesting a potential upside of 504.03%. Given Genelux's higher probable upside, analysts clearly believe Genelux is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Genelux has lower revenue, but higher earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50M	9.44	-$59.98M	-$1.95	N/A
Genelux	$8K	16,702.90	-$32.15M	-$0.85	N/A

In the previous week, Genelux had 1 more articles in the media than Contineum Therapeutics. MarketBeat recorded 3 mentions for Genelux and 2 mentions for Contineum Therapeutics. Genelux's average media sentiment score of 1.89 beat Contineum Therapeutics' score of 0.93 indicating that Genelux is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Contineum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genelux	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Genelux beats Contineum Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Genelux News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GNLX vs. The Competition

Export

Metric	Genelux	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$133.18M	$3.27B	$6.26B	$12.43B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	-3.49	17.91	22.42	24.23
Price / Sales	16,702.90	322.86	548.01	125.38
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	9.93	6.59	9.82	6.71
Net Income	-$32.15M	$24.20M	$3.56B	$337.09M
7 Day Performance	-2.61%	-3.13%	-1.17%	0.63%
1 Month Performance	8.76%	0.44%	3.71%	5.15%
1 Year Performance	15.95%	46.70%	27.28%	34.36%

Genelux Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GNLX Genelux	3.1665 of 5 stars	$2.98 +1.0%	$18.00 +504.0%	+20.4%	$133.18M	$8K	N/A	10	News Coverage
PRME Prime Medicine	1.8971 of 5 stars	$2.97 flat	$7.65 +157.6%	N/A	$536.44M	$4.63M	N/A	N/A	News Coverage
EIKN EIKN	N/A	$9.90 -9.3%	$25.20 +154.5%	N/A	$535.98M	N/A	N/A	384	Analyst Forecast
PRTA Prothena	2.9536 of 5 stars	$10.06 +2.3%	$21.78 +116.5%	+97.2%	$526.64M	$9.68M	N/A	130	Positive News
KYTX Kyverna Therapeutics	2.0148 of 5 stars	$8.61 -0.7%	$30.00 +248.4%	+198.1%	$523.40M	N/A	N/A	96	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GNLX) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genelux (GNLX) Competitors

GNLX vs. PRME, EIKN, PRTA, KYTX, and CTNM

How does Genelux compare to Prime Medicine?

Summary

How does Genelux compare to Eikon Therapeutics?

Summary

How does Genelux compare to Prothena?

Summary

How does Genelux compare to Kyverna Therapeutics?

Summary

How does Genelux compare to Contineum Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNLX vs. The Competition

Genelux Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genelux (GNLX) Competitors

GNLX vs. PRME, EIKN, PRTA, KYTX, and CTNM

How does Genelux compare to Prime Medicine?

Is PRME or GNLX more profitable?

Do analysts recommend PRME or GNLX?

Does the media refer more to PRME or GNLX?

Which has preferable earnings & valuation, PRME or GNLX?

Do institutionals and insiders believe in PRME or GNLX?

Which has more volatility & risk, PRME or GNLX?

Summary

How does Genelux compare to Eikon Therapeutics?

Do insiders and institutionals believe in EIKN or GNLX?

Is EIKN or GNLX more profitable?

Which has better earnings & valuation, EIKN or GNLX?

Do analysts rate EIKN or GNLX?

Does the media favor EIKN or GNLX?

Summary

How does Genelux compare to Prothena?

Does the media refer more to PRTA or GNLX?

Which has more risk & volatility, PRTA or GNLX?

Do institutionals and insiders have more ownership in PRTA or GNLX?

Which has higher valuation & earnings, PRTA or GNLX?

Do analysts prefer PRTA or GNLX?

Is PRTA or GNLX more profitable?

Summary

How does Genelux compare to Kyverna Therapeutics?

Does the media prefer KYTX or GNLX?

Which has stronger valuation & earnings, KYTX or GNLX?

Do analysts prefer KYTX or GNLX?

Do institutionals & insiders believe in KYTX or GNLX?

Is KYTX or GNLX more profitable?

Which has more risk and volatility, KYTX or GNLX?

Summary

How does Genelux compare to Contineum Therapeutics?

Is CTNM or GNLX more profitable?

Do insiders & institutionals have more ownership in CTNM or GNLX?

Which has more volatility & risk, CTNM or GNLX?

Do analysts recommend CTNM or GNLX?

Which has preferable valuation & earnings, CTNM or GNLX?

Does the media refer more to CTNM or GNLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNLX vs. The Competition

Genelux Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools